Ocrevus Subcutaneous
Roche has recently announced that the European Commission has granted marketing authorisation for Ocrevus (ocrelizumab) subcutaneous (under the skin) injection (Ocrevus SC). This new 10-minute administration offers comparable efficacy and safety to the existing intravenous (IV) infusion, providing a significant advancement for people living with relapsing multiple sclerosis and primary progressive multiple sclerosis.